Kovack Advisors, Inc. Ardelyx, Inc. Transaction History
Kovack Advisors, Inc.
- $985 Million
- Q4 2024
A detailed history of Kovack Advisors, Inc. transactions in Ardelyx, Inc. stock. As of the latest transaction made, Kovack Advisors, Inc. holds 17,933 shares of ARDX stock, worth $90,382. This represents 0.01% of its overall portfolio holdings.
Number of Shares
17,933Holding current value
$90,382% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding ARDX
# of Institutions
233Shares Held
150MCall Options Held
1.54MPut Options Held
3.08M-
Janus Henderson Group PLC London, X024.4MShares$123 Million0.07% of portfolio
-
Black Rock Inc. New York, NY17.6MShares$88.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA14.4MShares$72.4 Million0.0% of portfolio
-
State Street Corp Boston, MA11.6MShares$58.4 Million0.0% of portfolio
-
Macquarie Group LTD Australia, C310.3MShares$52.1 Million0.06% of portfolio
About ARDELYX, INC.
- Ticker ARDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 154,636,000
- Market Cap $779M
- Description
- Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...